AZN Astrazeneca RESULTS: Q2, Q2 REV $15.384B vs. EST $15.459B, Q2 core EPS $2.63 vs. EST $2.48, Q2 core operating margin 34%, Astrazeneca Ea
AZN Astrazeneca RESULTS: Q2, Q2 REV $15.384B vs. EST $15.459B, Q2 core EPS $2.63 vs. EST $2.48, Q2 core operating margin 34%, Astrazeneca Earnings Notes:, Remain confident in strength of our pipeline and have more than twenty high-value readouts due over next 18 months (more)
AZN Astrazeneca RESULTS: Q2, Q2 REV $15.384B vs.
EST $15.459B, Q2 core EPS $2.63 vs.
EST $2.48, Q2 core operating margin 34%, Astrazeneca Earnings Notes:, Remain confident in strength of our pipeline and have more than twenty high-value readouts due over next 18 months (more)